A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency
Molecular Therapy - Methods & Clinical Development · 2024-06 · 32 (2) · 101228
DOI: 10.1016/j.omtm.2024.101228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2024-06. Verfasst von Yoko Marwidi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sangamo Therapeutics, 501 Canal Boulevard, Richmond, CA 94804, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sangamo Therapeutics.
Abstract (Originalsprache)
Manufacturing of adeno-associated viruses (AAV) for gene and cell therapy applications has increased significantly and spurred development of improved mammalian and insect cell-based production systems. We developed a baculovirus-based insect cell production system-the SGMO Helper-with a novel gene architecture and greater flexibility to modulate the expression level and content of individual Rep and Cap proteins. In addition, we incorporated modifications to the AAV6 capsid sequence that improves yield, capsid integrity, and potency. Production of recombinant AAV 6 (rAAV6) using the SGMO Helper had improved yields compared to the Bac-RepCap helper from the Kotin lab. SGMO Helper-derived rAAV6 is resistant to a previously described proteolytic cleavage unique to baculovirus-insect cell production systems and has improved capsid ratios and potency, in vitro and in vivo, compared with rAAV6 produced using Bac-RepCap. Next-generation sequencing sequence analysis demonstrated that the SGMO Helper is stable over six serial passages and rAAV6 capsids contain comparable amounts of non-vector genome DNA as rAAV6 produced using Bac-RepCap. AAV production using the SGMO Helper is scalable using bioreactors and has improved yield, capsid ratio, and in vitro potency. Our studies demonstrate that the SGMO Helper is an improved platform for AAV manufacturing to enable delivery of cutting-edge gene and cell therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sangamo Therapeutics, 501 Canal Boulevard, Richmond, CA 94804, USA.
Förderung
- Sangamo Therapeutics
Zitieren
APA
Marwidi, Y., Nguyen, H. B., Santos, D., Wangzor, T., Bhardwaj, S., Ernie, G., Prawdzik, G., Lew, G., Shivak, D., Trias, M., Padilla, J., Tran, H., Meyer, K., Surosky, R., & Ward, A. M. (2024). A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency. Molecular Therapy - Methods & Clinical Development, 32(2), 101228. https://doi.org/10.1016/j.omtm.2024.101228
Vancouver
Marwidi Y, Nguyen HB, Santos D, Wangzor T, Bhardwaj S, Ernie G, et al. A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency. Molecular Therapy - Methods & Clinical Development. 2024;32(2):101228. doi:10.1016/j.omtm.2024.101228
BibTeX
@article{Marwidi2024,
author = {Marwidi, Yoko and Nguyen, Hoang-Oanh B and Santos, David and Wangzor, Tenzin and Bhardwaj, Sumita and Ernie, Gabriel and Prawdzik, Gregg and Lew, Garrett and Shivak, David and Trias, Michael and Padilla, Jada and Tran, Hung and Meyer, Kathleen and Surosky, Richard and Ward, Alex Michael},
title = {A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2024},
volume = {32},
number = {2},
pages = {101228},
doi = {10.1016/j.omtm.2024.101228}
}
EUVIMED